Title |
REVIEW] Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies |
Author |
Brian B. Gowen* and Brady T. Hickerson |
Address |
Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, 84326, USA |
Bibliography |
Journal of Microbiology, 55(3),183-195, 2017,
|
DOI |
10.1007/s12275-017-7029-8
|
Key Words |
bunyavirus, Rift valley fever, severe fever with
thrombocytopenia syndrome, Crimean-Congo hemorrhagic
fever, hantavirus, antiviral |
Abstract |
A growing number of bunyaviruses are known to cause viral
hemorrhagic fever (VHF), a severe febrile illness which can
progress to hypovolemic shock and multi-organ failure and
is characterized by hematologic abnormalities and vascular
leak. At present, there are no approved vaccines or antiviral
therapies to effectively prevent or treat VHF caused by pathogenic
bunyaviruses. Advances in the modeling of bunyaviral
infections have facilitated efforts towards the development
of novel post-exposure prophylactic and therapeutic
countermeasures, several of which may some day be approved
for human use. Here, we review recent progress in animal
models of severe bunyaviral infections essential to this mission,
as well as promising antivirals and biologicals that are
at various stages of the development process. |